What’s ahead for Abbott Laboratories’ Medical Device Unit?
Abbott Laboratories’ (ABT) Medical Device segment is its largest business division, contributing ~36% to the company’s total sales in 4Q17.
These Developments Impacted Abbott Laboratories the Most in Fiscal 2017
Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.
Boston Scientific Stock Triggered by FDA Approval of Vercise DBS
On December 11, 2017, Boston Scientific (BSX) stock rose 3%, triggered by FDA approval of its Vercise DBS (deep brain stimulation) system.
Inside Abbott’s Neuromodulation Business Growth
Abbott’s Medical Devices segment has products for rhythm management, heart failure, electrophysiology, structural heart diseases, neuromodulation, and more.
St. Jude’s Proclaim Elite SCS System Received CE Mark Approval
On December 8, 2016, St. Jude Medical (STJ) announced CE Mark approval for full body MR (magnetic resonance) conditional labeling for the Proclaim Elite SCS (spinal cord stimulation) System.
Nevro Lawsuit against BSX Could Impact Its Neuromodulation Revenues
On November 29, 2016, Nevro Corp. (NVRO) filed a lawsuit against Boston Scientific, claiming patent infringement on its patents for Senza and HF10 spinal cord stimulation therapies for chronic back pain.
How Have IHI’s Mid-Capitalization Stocks Performed?
On June 9, 2016, the top performer within the mid-capitalization space of the iShares U.S. Medical Devices ETF was Idexx Laboratories, which rose by 1.5%.
IHI’s Small Caps Outperformed the Market
Small-cap stocks in the iShares US Medical Devices ETF (IHI) went down by 0.15% and outperformed the SPDR S&P 500 ETF (SPY) and the IHI itself.